PublicationsPublicationsPublicationsPublications
  • HOME
    • Our mission
    • Our lead product
  • STORY
  • ELENAVET
    • How does it work
      • Cancer
      • Non-cancer diseases
    • What is ElenaVet?
  • CLINICS
    • Partnering
    • Regulatory
  • TEAM
    • Management
    • Advisory Board
  • INVESTORS
    • Download our One-Pager investor prospectus
    • Market size
  • IP
  • PUBLICATION
  • LEGAL
  • CONTACT
  • NEWS

Publications

  • P62-DNA-encoding plasmid reverts tumor grade, changes tumor stroma, and enhances anticancer immunity
  • Pilot Study of p62 DNA Vaccine in Dogs with Mammary Tumors
  • Response of a chemo-resistant triple-negative breast cancer patient to a combination of p62-encoding plasmid, Elenagen, and CMF chemotherapy
  • Broad-spectrum Anti-tumor and Anti-metastatic DNA Vaccine based on p62-encoding Vector
  • Safety and efficacy of p62 DNA vaccine ELENAGEN in a first-in-human trial in patients with advanced solid tumors
  • Plasmid DNA-coding p62 as a Bone Effective Anti-inflammatory/Anabolic Agent
  • P62 plasmid can alleviate diet-induced obesity and metabolic dysfunctions
  • p62 /SQSTM1 coding plasmid prevents age related macular degeneration in a rat model
  • p62 / SQSTM1 Expression In Canine Mammary Tumours: Evolutionary Notes
  • Safety and efficacy of p62 DNA vaccine ELENAGEN in a first-in-human trial in patients with advanced solid tumors
  • Neuroprotective effects of p62(SQSTM1)-engineered lactic acid bacteria in Alzheimer’s disease: a pre-clinical study
© 2023 CureLab Veterinary
    video

    Sequence 01